poisar

Stocks · News reference

GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.

BenzingaJul 17, 2026, 5:29 PMBenzinga Newsdesk

GSK Plans To Stop Further Development Of In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 17, 2026, 5:29 PM
Checked
Jul 17, 2026, 5:29 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading